Liquid Biopsy Market Size to Reach $5.96 Billion by 2030: Grand View Research, Inc.

Print 09 September 2016
PRNewswire

SAN FRANCISCO, September 8, 2016 /PRNewswire/ -- Global liquid biopsies market is anticipated to reach 5,958.3 million by 2030, according to a new report by Grand View Research, Inc. As these less invasive biopsies are able to address a number of significant challenges associated with conventional biopsies such as, high level of invasiveness, incompleteness of cancer information that is acquired, associated post-biopsy serious medical complications, and subsequent cost inclusions. A growing need for more advanced, efficient and accurate method which provides a holistic view of the tumor and metastasis is the prime factor fueling rapid development of liquid biopsies.

The market has gained considerable traction in the past couple of years. A number of clinical research projects related to circulating tumor cells, and cell-free tumor DNA have been initiated in the latter half of the past decade. As a result, there are a number of ongoing clinical trials that are due to be completed between post 2017-18. It is expected that upon successful completion, commercialization of these assays and tests will provide the market a significant boost in potential addressable target revenue and fuel growth through to 2030.

Browse full research report with TOC on "Liquid Biopsy Market Size & Forecast By Application (Therapy Selection for Metastatic Breast Cancer (MBS), Therapy Selection for Other Metastatic Cancers, Molecular Monitoring, Molecular Monitoring), By Sample Type (Blood, Urine, Tissue & Saliva), By Biomarker Type (Circulating Tumor Cells (CTC), Circulating Tumor DNA (ctDNA), Exosomes), By Technology (Single Gene Analysis (PCR Microarrays), Multi-gene-parallel Analysis (NGS)) And Trend Analysis from 2013 To 2030" at:http://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market

Further key findings from the report suggest: 

• In terms of applications, therapy selection of metastatic cancers is the key area of liquid biopsy usage as these provide significant insights into the unique genetic information encoded in CTCs and ctDNAs. Furthermore, with the addition of more research data reinforcing the usage of liquid biopsies over the coming years, it is expected that their application for molecular monitoring of diseases will also be a lucrative source of revenue through to 2030
• Key biomarkers that any liquid biopsy targets include circulating tumor cells, circulating tumor DNA and exosomes that are macrovesicles containing tumor RNA, or tumor protein freely circulating in the patient's bloodstream. Assays for ctDNA are expected to account for the largest share of revenue through to 2030 owing to the currently present assays and expected number of products that are to be commercialized over the coming decade.
• Development of parallel multi-gene analysis using next generation sequencing technology is the underlying factor that has enabled oncologists to more efficiently sequence ctDNA and gain insights related to cancer metastasis and the related mechanism. This understanding provides a patient-centric systemic view of cancer and aids in its long term monitoring.
• North America, specifically the U.S. accounts for the largest share of revenue for the development of liquid biopsy market. The region was observed to account for around 50% of the global potential in 2015 owing to the high number clinical development projects underway for the commercialization of CTC and ctDNA assays till 2020. Furthermore, throughout the forecast period, U.S. is expected to dominate revenue generation owing to the dynamic nature & being the region of prime activity, research and development with respect to liquid biopsy and next generation sequencing technology.
• Although, post successful commercialization through to 2030, Asia Pacific is expected to be a lucrative region for development as it is expected to be characterized by the presence of a large patient population base, developing healthcare framework and growth in integration of more advanced healthcare practices.
• The market is in its developing phase and is characterized by the presence of a number of relatively smaller entities involved in innovation and new product development. Companies such as Biocept, Adaptive Biotechnologies, NeoGenomics Laboratories, Guardant Health, Qiagen, Personal Genome Diagnostics, Cynvenio, RainDance Technologies, and Trovagene are operating in the space and have a number of commercialized assays in their portfolios for liquid biopsy. 
• Furthermore, as this space has a high lucrative potential, and is considerably influenced by the developments in NGS technology, there are a number of major players that have on-going investigational & observational clinical trials and are due to be completed by 2017 to 2019. Collectively, over 30 clinical trials are currently registered as active by companies including Illumina, Foundation Medicine, Natera Inc., Roche, Sequenom, LabCorp, Epic Sciences, and Pathway Genomics in the U.S. alone. Anticipated successful commercialization of these products is expected to fuel growth over the forecast period.

Source

Return